Mitochondrial disorders are debilitating and life-threatening diseases that still lack effective treatment. They are due to genetic defects affecting oxidative phosphorylation, thus mitochondrial fitness and ATP production.
Patients with complex III dysfunction develop progressive neurological impairment, myopathy and meet an early death. Currently, no treatment for such pathologies exist.
We have developed a pharmaceutical strategy to “replace” the defective complex III. We found that redox cyclers (compounds undergoing reduction to form radical species that can then react with oxygen, thus regenerating the parent molecule), such as pyocyanin, can recover the mitochondrial function in patient-derived cells and ameliorate the pathological phenotypes animal models of complex III deficiency. Similar results were obtained in disease models linked to mitochondrial complex I dysfunction as well.
See also Peruzzo et al., Nat Commun (2021).

TRL (Technology Readiness Level)

TRL 4 / 9

Inventors

Ildiko
Szabò

Roberta
Peruzzo

Mario
Zoratti

Rodolfo
Costa

Massimo
Zeviani

Download the brochure

  • TREM2MICROENGINES – Novel Regulated Promoter for Gene Therapy

    Neuroinflammation, characterized by microglial cell-activation, plays a major role in the pathogenesis and progression of multiple neurodegenerative diseases, such as Lysosomal Storage Disorders and Alzheimer’s, severe human conditions currently lacking an effective treatment. Ex vivo gene therapy based on genetically[...]

  • CuRE – Copper complexes as novel anticancer agents

    Although platinum-based drugs, such as cisplatin, have achieved great success in cancer treatment and are presently enclosed in the majority of clinical protocols for the management of solid malignancies, their use are associated with significant drawbacks such as severe toxic[...]

  • Bicyclic peptides for targeted therapy against cancer

    Since inhibitors based on small molecules and macromolecules are not selective and potent enough, new compounds, including bicyclic peptides, have been developed in recent years. Bicyclic peptides are new generation therapeutic molecules which exhibit properties typical of monoclonal antibodies (high[...]

Subscribe to newsletter

Follow the activities promoted by UniSMART Foundation